Zegerid Powder, For Suspension
NDC Package 68012-052-30

11-digit billing NDC: 68012005230 · Billing unit: EA · 30 EA per package

Package Information

Zegerid (omeprazole and sodium bicarbonate) powders is zEGERID for oral suspension and ZEGERID capsules are indicated in adults for the:•short-term treatment of active duodenal ulcer. This formulation utilizes a powder, for suspension delivery system. Marketed by Santarus, Inc.., this product is identified by NDC 68012-052 and is authorized under FDA application NDA021636.

Identification & Billing

NDC Package Code
68012-052-30
Package Description
30 PACKET in 1 CARTON / 1 POWDER, FOR SUSPENSION in 1 PACKET
Product Code
11-Digit Billing Format
68012005230
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
30 EA
RxNorm Crosswalk
  • RxCUI: 616539 - omeprazole 20 MG / sodium bicarbonate 1100 MG Oral Capsule
  • RxCUI: 616539 - Omeprazole 20 MG / NaHCO3 1100 MG Oral Capsule
  • RxCUI: 616541 - omeprazole 40 MG / sodium bicarbonate 1100 MG Oral Capsule
  • RxCUI: 616541 - Omeprazole 40 MG / NaHCO3 1100 MG Oral Capsule
  • RxCUI: 646344 - Zegerid 20 MG / 1100 MG Oral Capsule, Reformulated Aug 2006

Clinical Specifications

Proprietary Name
Zegerid
Non-Proprietary Name
Omeprazole And Sodium Bicarbonate
Substance Name
Omeprazole; Sodium Bicarbonate
Dosage Form
Powder, For Suspension - An intimate mixture of dry, finely divided drugs and/or chemicals, which, upon the addition of suitable vehicles, yields a suspension (a liquid preparation containing the solid particles dispersed in the liquid vehicle).
Administration Route
Oral - Administration to or by way of the mouth.
Usage Information
ZEGERID for oral suspension and ZEGERID capsules are indicated in adults for the:•short-term treatment of active duodenal ulcer. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy.•short-term treatment (4 to 8 weeks) of active benign gastric ulcer.•treatment of heartburn and other symptoms associated with GERD for up to 4 weeks.•short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD which has been diagnosed by endoscopy in adults.oThe efficacy of ZEGERID used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8-week courses of ZEGERID may be considered.•maintenance of healing of EE due to acid-mediated GERD. Controlled studies do not extend beyond 12 months.ZEGERID for oral suspension is indicated in adults for the:•reduction of risk of upper GI bleeding in critically ill adult patients.

Regulatory & Marketing

Labeler Name
Santarus, Inc..
Product Type
Human Prescription Drug
FDA Application #
NDA021636
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
06-15-2004
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 68012-052-30 identifies a specific commercial package of 30 packet in 1 carton / 1 powder, for suspension in 1 packet of Zegerid, a human prescription drug labeled by Santarus, Inc... This powder, for suspension is formulated for oral use and contains omeprazole; sodium bicarbonate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Santarus, Inc.. on June 15, 2004. The current certification is valid through December 31, 2027.

How is this Santarus, Inc.. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 68012005230. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
68012-052-30
11-Digit CMS (5-4-2)
68012-0052-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.